Market Cap 4.47B
Revenue (ttm) 0.00
Net Income (ttm) -252.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,790,200
Avg Vol 2,511,178
Day's Range N/A - N/A
Shares Out 82.32M
Stochastic %K 64%
Beta -0.35
Analysts Sell
Price Target $67.44

Company Profile

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 487 6488
Website: akerotx.com
Address:
601 Gateway Boulevard, Suite 350, South San Francisco, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 1:12 AM
$AKRO: The last close of $54.2 indicates a strong position near the 60D high of $54.53. The RSI of 65.69 suggests the stock is nearing overbought territory, indicating potential for a pullback or consolidation. The MA30 at $52.91 and MA50 at $49.91 both indicate upward momentum, supporting a bullish bias in the short term. However, the proximity to the 60D high may limit upside potential. Suggested entry: $54.0 to capitalize on potential short-term strength. Stop loss: $53.0 to manage risk below the MA30. Targets: First target at $55.0, just above the 60D high, and a second target at $56.0, allowing for further upside if momentum continues. Overall, while bullish sentiment is present, caution is warranted due to the RSI level and proximity to recent highs. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:45 AM
$AKRO: The last close of $54.2 indicates a strong position near the 60D high of $54.53. The RSI of 65.69 suggests the stock is nearing overbought territory, indicating potential for a pullback or consolidation. The MA30 at $52.91 and MA50 at $49.91 both indicate upward momentum, supporting a bullish bias in the short term. However, the proximity to the 60D high may limit upside potential. Suggested entry: $54.0 to capitalize on potential short-term strength. Stop loss: $53.0 to manage risk below the MA30. Targets: First target at $55.0, just above the 60D high, and a second target at $56.0, allowing for further upside if momentum continues. Overall, while bullish sentiment is present, caution is warranted due to the RSI level and proximity to recent highs. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:51 AM
$AKRO is currently trading at $54.25, near the 60-day high of $54.53, indicating strong bullish momentum. The RSI of 73.19 suggests that the stock is overbought, which could lead to a pullback. The 30-day moving average (MA30) at $52.39 and the 50-day moving average (MA50) at $49.54 provide support levels, indicating a bullish trend in the short to medium term. Given the overbought RSI and proximity to the 60-day high, a cautious approach is warranted. Suggested entry could be around $54.00, with a stop loss at $52.00 to manage risk. If the stock holds above the MA30, targets could be set at $55.00 and $56.00, capitalizing on potential continuation if momentum persists. Overall, the directional bias is bullish, but traders should be prepared for possible volatility due to the high RSI. https://privateprofiteers.com
0 · Reply
Orkay
Orkay Nov. 12 at 8:30 PM
$VKTX $MTSR $ETNB $AKRO bought out in past 3 months. Viking is far ahead of them and MASH assets. $15B min.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:27 AM
$AKRO is currently trading at $54.25, near the 60-day high of $54.53, indicating strong bullish momentum. The RSI of 73.19 suggests that the stock is overbought, which could lead to a pullback. The 30-day moving average (MA30) at $52.39 and the 50-day moving average (MA50) at $49.54 provide support levels, indicating a bullish trend in the short to medium term. Given the overbought RSI and proximity to the 60-day high, a cautious approach is warranted. Suggested entry could be around $54.00, with a stop loss at $52.00 to manage risk. If the stock holds above the MA30, targets could be set at $55.00 and $56.00, capitalizing on potential continuation if momentum persists. Overall, the directional bias is bullish, but traders should be prepared for possible volatility due to the high RSI. https://privateprofiteers.com
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 12 at 2:02 AM
$AKRO Hopefully enough shareholders do the right thing and block $NVO steal! This should be a minimum $75, not $54 + 6. JMO
0 · Reply
quickaspeter
quickaspeter Nov. 12 at 1:58 AM
$AKRO $ALT $MDGL Great insight…thanks for sharing!!!
0 · Reply
BTECHINV
BTECHINV Nov. 12 at 1:48 AM
$ALT My take post-AASLD, Pemvi is a master metabolic regulator, outstanding Scientific progress: 1- GLP-1 class leading MASH RESOLUTION at 24W 2- Higher MASH RES. than all but one of leading FGF21's (essentially statistically tied) 3- FDA requires single trad EP in P3 for approval (see #1), Pemvi stat sig at 24W already below p<0.0001, remarkable 4- EU has approved PathAI, FDA currently reviewing 5- Powerful Stat. Sig anti-Fibrosis per leading DP/AI HistoP technology 6- ABSOLUTE trad. Path Fibro very strong, basically FGF21 like (Placebo values were outlier IMO); FGF21 is downstream of GCG biologically (Pemvi eff. shows that) 7- DP/AI will play KEY role characterizing drugs from here on out, $AKRO $MDGL utilizing 8- NITs & composite biomarkers WILL be way MASH is managed in the field; benefits drug candidate w/ PEMVI's broad biological profile 9- PEMVI WL w/ Lean Mass + Metabolism is major+ for Scripts/Market share potential 10- Excellent safety profile to date Long ALT, not med/inv advice
3 · Reply
DG20
DG20 Nov. 11 at 8:55 PM
$AKRO $ETNB $MDGL $VKTX Pemvidutide is the only GLP that does NOT treat diabetes. STOP SPAMMING the Viking board!!!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:51 PM
$ALT $VKTX $ETNB $AKRO $MDGL Let’s not forget weight loss!
0 · Reply
Latest News on AKRO
My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 25 days ago

My Top 3 Pharma Stocks

BMY ETNB LLY MRK NVO PFE SPY


Akero Therapeutics Stock Soars on Novo Nordisk Deal.

Oct 9, 2025, 7:31 AM EDT - 5 weeks ago

Akero Therapeutics Stock Soars on Novo Nordisk Deal.

NVO


Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

Oct 9, 2025, 6:39 AM EDT - 5 weeks ago

Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

NVO


Novo Nordisk buys Akero Therapeutics in the US

Oct 9, 2025, 6:09 AM EDT - 5 weeks ago

Novo Nordisk buys Akero Therapeutics in the US

NVO


Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Apr 6, 2025, 1:47 PM EDT - 7 months ago

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock


PrivateProfiteer
PrivateProfiteer Nov. 15 at 1:12 AM
$AKRO: The last close of $54.2 indicates a strong position near the 60D high of $54.53. The RSI of 65.69 suggests the stock is nearing overbought territory, indicating potential for a pullback or consolidation. The MA30 at $52.91 and MA50 at $49.91 both indicate upward momentum, supporting a bullish bias in the short term. However, the proximity to the 60D high may limit upside potential. Suggested entry: $54.0 to capitalize on potential short-term strength. Stop loss: $53.0 to manage risk below the MA30. Targets: First target at $55.0, just above the 60D high, and a second target at $56.0, allowing for further upside if momentum continues. Overall, while bullish sentiment is present, caution is warranted due to the RSI level and proximity to recent highs. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:45 AM
$AKRO: The last close of $54.2 indicates a strong position near the 60D high of $54.53. The RSI of 65.69 suggests the stock is nearing overbought territory, indicating potential for a pullback or consolidation. The MA30 at $52.91 and MA50 at $49.91 both indicate upward momentum, supporting a bullish bias in the short term. However, the proximity to the 60D high may limit upside potential. Suggested entry: $54.0 to capitalize on potential short-term strength. Stop loss: $53.0 to manage risk below the MA30. Targets: First target at $55.0, just above the 60D high, and a second target at $56.0, allowing for further upside if momentum continues. Overall, while bullish sentiment is present, caution is warranted due to the RSI level and proximity to recent highs. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:51 AM
$AKRO is currently trading at $54.25, near the 60-day high of $54.53, indicating strong bullish momentum. The RSI of 73.19 suggests that the stock is overbought, which could lead to a pullback. The 30-day moving average (MA30) at $52.39 and the 50-day moving average (MA50) at $49.54 provide support levels, indicating a bullish trend in the short to medium term. Given the overbought RSI and proximity to the 60-day high, a cautious approach is warranted. Suggested entry could be around $54.00, with a stop loss at $52.00 to manage risk. If the stock holds above the MA30, targets could be set at $55.00 and $56.00, capitalizing on potential continuation if momentum persists. Overall, the directional bias is bullish, but traders should be prepared for possible volatility due to the high RSI. https://privateprofiteers.com
0 · Reply
Orkay
Orkay Nov. 12 at 8:30 PM
$VKTX $MTSR $ETNB $AKRO bought out in past 3 months. Viking is far ahead of them and MASH assets. $15B min.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:27 AM
$AKRO is currently trading at $54.25, near the 60-day high of $54.53, indicating strong bullish momentum. The RSI of 73.19 suggests that the stock is overbought, which could lead to a pullback. The 30-day moving average (MA30) at $52.39 and the 50-day moving average (MA50) at $49.54 provide support levels, indicating a bullish trend in the short to medium term. Given the overbought RSI and proximity to the 60-day high, a cautious approach is warranted. Suggested entry could be around $54.00, with a stop loss at $52.00 to manage risk. If the stock holds above the MA30, targets could be set at $55.00 and $56.00, capitalizing on potential continuation if momentum persists. Overall, the directional bias is bullish, but traders should be prepared for possible volatility due to the high RSI. https://privateprofiteers.com
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 12 at 2:02 AM
$AKRO Hopefully enough shareholders do the right thing and block $NVO steal! This should be a minimum $75, not $54 + 6. JMO
0 · Reply
quickaspeter
quickaspeter Nov. 12 at 1:58 AM
$AKRO $ALT $MDGL Great insight…thanks for sharing!!!
0 · Reply
BTECHINV
BTECHINV Nov. 12 at 1:48 AM
$ALT My take post-AASLD, Pemvi is a master metabolic regulator, outstanding Scientific progress: 1- GLP-1 class leading MASH RESOLUTION at 24W 2- Higher MASH RES. than all but one of leading FGF21's (essentially statistically tied) 3- FDA requires single trad EP in P3 for approval (see #1), Pemvi stat sig at 24W already below p<0.0001, remarkable 4- EU has approved PathAI, FDA currently reviewing 5- Powerful Stat. Sig anti-Fibrosis per leading DP/AI HistoP technology 6- ABSOLUTE trad. Path Fibro very strong, basically FGF21 like (Placebo values were outlier IMO); FGF21 is downstream of GCG biologically (Pemvi eff. shows that) 7- DP/AI will play KEY role characterizing drugs from here on out, $AKRO $MDGL utilizing 8- NITs & composite biomarkers WILL be way MASH is managed in the field; benefits drug candidate w/ PEMVI's broad biological profile 9- PEMVI WL w/ Lean Mass + Metabolism is major+ for Scripts/Market share potential 10- Excellent safety profile to date Long ALT, not med/inv advice
3 · Reply
DG20
DG20 Nov. 11 at 8:55 PM
$AKRO $ETNB $MDGL $VKTX Pemvidutide is the only GLP that does NOT treat diabetes. STOP SPAMMING the Viking board!!!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:51 PM
$ALT $VKTX $ETNB $AKRO $MDGL Let’s not forget weight loss!
0 · Reply
PemvidutideTrader7B
PemvidutideTrader7B Nov. 11 at 8:36 PM
$ALT $VKTX $ETNB $AKRO $MDGL Huge start out of the gates for Altimmune.
0 · Reply
Sd1682
Sd1682 Nov. 10 at 6:06 PM
$AKRO so when is there earnings one app says today and others say 21st that used say 18th
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 10 at 1:59 AM
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith $NVO $PFE $MTSR $AKRO $VKTX https://stocktwits.com/news/equity/markets/novo-nordisk-loses-metsera-bidding-war-to-pfizer-but-retail-traders-aren-t-losing-faith/cLPcRJWREci
0 · Reply
Theverypatientone
Theverypatientone Nov. 8 at 6:04 PM
$ALT BIC - $AKRO , $MTSR $MDGL $VKTX etc lag behind in both MASH, preserving muscle mass AUD, ALD and cardio vascular improvements.
3 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 8 at 12:36 PM
$AKRO Unbelievable how cheap it is selling out! It has money to carry out the clinical trials leading to approval. JMO
0 · Reply
ApesOnParade
ApesOnParade Nov. 7 at 2:45 PM
$ALT — Pemvidutide Phase 2 🔥 Altimmune delivered major results in MASH (fatty liver disease): ✅ 58% MASH resolution vs 9% placebo ✅ 5–6% avg. weight loss ✅ Early anti-fibrotic signal ✅ Excellent safety (≤2% dropouts) Pemvidutide is a dual GLP-1 + glucagon agonist, targeting both metabolism and liver fibrosis — something $NVO and $LLY haven’t nailed yet. MASH/NASH market = $20–30B+ by 2030 with few effective drugs. Data positions $ALT as a front-runner. Competitors: $MDGL (fibrosis focus, no WL) $NVO (strong WL, mixed fibrosis) $AKRO (potent, GI issues) $ALT = balanced efficacy + safety. Phase 3 (2025–26) is next. If results hold, FDA approval odds are strong. 💡 Undervalued near $600M MC. 4–6× upside if Phase 3 confirms.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 3:21 PM
0 · Reply
HOSTS777
HOSTS777 Oct. 29 at 2:41 PM
$AKRO there is a little fight here today. picking up every drop under 54
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 27 at 10:00 PM
Results $ALL $ALKS $AKRO $AKAM $AJG 🔥
0 · Reply
Johnquest123
Johnquest123 Oct. 27 at 1:36 PM
$ABBV $AKRO $NVO $PFE $VKTX so you have this moron here basically praying for BO no one is left. ABBV is developing Gubr for $3 billion.
0 · Reply
RetiredFl2021
RetiredFl2021 Oct. 27 at 12:06 PM
$ALT $NVO $AKRO For your reading pleasure, here’s a detailed chronology of Novo Nordisk’s acquisition of Akero Therapeutics.
2 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:03 PM
List 10/10 to 10/24 Results $AKRO $ALE $ALG $ALGN $ALK 🔥 Cycle Trading Signal plugged into AI 🔥
0 · Reply